U01AI174268
Cooperative Agreement
Overview
Grant Description
TB-RICC 3.0 - TB-RICC 3.0 is designed to support the Regional Prospective Observational Research Tuberculosis (REPORT) Consortium to produce the highest quality observational and interventional research on tuberculosis (TB), TB-HIV, and TB-COVID-19. To accomplish this goal, TB-RICC 3.0 will:
I) Collaborate with REPORT country-network data centers and biorepositories to ensure that common data elements (CDE) of the common protocol and specimen tracking are accessible through the global data template.
II) Organize and/or strengthen select sites to participate in diagnostic studies and clinical trials.
III) Support the REPORT country-networks to ensure further development of TB diagnostic laboratories, TB-RICC 3.0 specialized laboratories, and biorepositories.
The aims of TB-RICC 3.0 are:
Coordinating Center Structure and Function:
- Develop a leadership group and executive committee.
- Assure effective communication internally and externally.
- Establish a data hub to provide seamless data management from collection to analysis.
- Establish scientific working groups, a scientific review committee, and an administrative core.
- Facilitate grant submissions to potential funders and partners.
Data Harmonization:
- Develop a data hub to collaborate with country-level data centers to facilitate multiregional data workflow using the REDCap Harmonist platform and other tools.
Research:
- Catalyze TB, TB/HIV, and TB/COVID-19 research within and across REPORT country networks, and with external partners.
- Prioritize the study of TB close contacts to evaluate biomarkers predictive of progression to TB across three "omics" platforms and three continents.
Capacity Building:
- Develop modular remote courses for capacity building in the components of TB research.
- Mentor early-stage investigator (ESI) development.
TB-RICC 3.0 will deliver high-impact innovative research to advance TB science and TB control.
I) Collaborate with REPORT country-network data centers and biorepositories to ensure that common data elements (CDE) of the common protocol and specimen tracking are accessible through the global data template.
II) Organize and/or strengthen select sites to participate in diagnostic studies and clinical trials.
III) Support the REPORT country-networks to ensure further development of TB diagnostic laboratories, TB-RICC 3.0 specialized laboratories, and biorepositories.
The aims of TB-RICC 3.0 are:
Coordinating Center Structure and Function:
- Develop a leadership group and executive committee.
- Assure effective communication internally and externally.
- Establish a data hub to provide seamless data management from collection to analysis.
- Establish scientific working groups, a scientific review committee, and an administrative core.
- Facilitate grant submissions to potential funders and partners.
Data Harmonization:
- Develop a data hub to collaborate with country-level data centers to facilitate multiregional data workflow using the REDCap Harmonist platform and other tools.
Research:
- Catalyze TB, TB/HIV, and TB/COVID-19 research within and across REPORT country networks, and with external partners.
- Prioritize the study of TB close contacts to evaluate biomarkers predictive of progression to TB across three "omics" platforms and three continents.
Capacity Building:
- Develop modular remote courses for capacity building in the components of TB research.
- Mentor early-stage investigator (ESI) development.
TB-RICC 3.0 will deliver high-impact innovative research to advance TB science and TB control.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Newark,
New Jersey
071073001
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 100% from $7,866,834 to $15,695,547.
Rutgers The State University Of New Jersey was awarded
TB-RICC 3.0
Cooperative Agreement U01AI174268
worth $15,695,547
from the National Institute of Allergy and Infectious Diseases in April 2023 with work to be completed primarily in Newark New Jersey United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.855 Allergy and Infectious Diseases Research.
The Cooperative Agreement was awarded through grant opportunity RePORT International Coordinating Center (RICC) (U01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 6/5/26
Period of Performance
4/1/23
Start Date
3/31/28
End Date
Funding Split
$15.7M
Federal Obligation
$0.0
Non-Federal Obligation
$15.7M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for U01AI174268
Transaction History
Modifications to U01AI174268
Additional Detail
Award ID FAIN
U01AI174268
SAI Number
U01AI174268-1263881497
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NM00 NIH National Institute of Allergy and Infectious Diseases
Funding Office
75NM00 NIH National Institute of Allergy and Infectious Diseases
Awardee UEI
YVVTQD8CJC79
Awardee CAGE
6VL59
Performance District
NJ-10
Senators
Robert Menendez
Cory Booker
Cory Booker
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases, National Institutes of Health, Health and Human Services (075-0885) | Health research and training | Grants, subsidies, and contributions (41.0) | $3,933,417 | 100% |
Modified: 6/5/26